Elevated serum amylase affects clinical outcomes in COVID-19

Key clinical point: Elevated serum amylase (ESA) was associated with adverse clinical outcomes and mortality in hospitalized patients with COVID-19.

Major finding: Hyperamylasemia (amylase > upper limit of normal [ULN] of 115 U/L) was independently associated with mortality (1-3-times ULN [1-3 ULN]: hazard ratio [HR] 1.63; P = .034; >3-fold ULN [>3 ULN]: HR 8.90; P < .001) and adverse outcomes (all P < .001), such as sepsis (1-3 ULN: odds ratio [OR] 1.15; >3 ULN: OR 1.87), disseminated intravascular coagulation (1-3 ULN: OR 1.13; >3 ULN: OR 1.65), cardiac injury (1-3 ULN: OR 1.24; >3 ULN: OR 1.71), acute respiratory distress syndrome (1-3 ULN: OR 1.21; >3 ULN: OR 1.62), and acute kidney injury (1-3 ULN: OR 1.24; >3 ULN: OR 1.79).

Study details: This retrospective study included 1,515 inpatients with COVID-19. Overall, 196 patients had ESA, of which 9.7% had an ESA of >3 ULN.

,

Disclosures: This study was supported by the National Nature Science Foundation of China and Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province. The authors declared no conflict of interests.

Source: Li G et al. Aging (Albany NY). 2021(Oct 29);13(20):23442-23458. Doi: 10.18632/aging.203653.